WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles:
Related suggestion:
China Focus: Record Qingming holiday box office heats up for May Day moviegoing frenzyUS smears, blames China, and shirks its own responsibility on fentanyl issue: Chinese FMOne dead and two critical after a wannabe trucker who failed his test deliberately plowed his 18BRI promotes modernization, mutual benefitAnger as new Rector claims Glasgow University 'colludes in murder of innocents'Uninsured driver, 33, who hit district judge with his car seconds before the father'Liusanjie of New Generation' Sings for New EraChris Packham joins ecoCommentary: Message of peace for crossResidents of Beijing
2.4053s , 6503.3671875 kb
Copyright © 2024 Powered by Why Amylyx is pulling ALS drug Relyvrio from US market after study ,Culture Channel news portal